Agios Pharmaceuticals (NASDAQ:AGIO) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research report sent to investors on Wednesday,Benzinga reports.

A number of other equities research analysts have also recently weighed in on the company. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Scotiabank upped their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. Raymond James restated an “outperform” rating and set a $51.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Royal Bank of Canada upped their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Finally, Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $60.00 to $56.00 in a report on Friday, September 27th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $56.33.

Agios Pharmaceuticals Stock Down 1.1 %

NASDAQ:AGIO opened at $35.42 on Wednesday. Agios Pharmaceuticals has a 12-month low of $20.96 and a 12-month high of $62.58. The firm has a market capitalization of $2.02 billion, a price-to-earnings ratio of 3.12 and a beta of 0.80. The stock’s 50 day moving average price is $49.94 and its two-hundred day moving average price is $46.71.

Insider Activity

In related news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. 4.93% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AGIO. Acadian Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth $37,000. Quest Partners LLC bought a new stake in Agios Pharmaceuticals during the second quarter worth about $40,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Agios Pharmaceuticals by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 363 shares in the last quarter. CWM LLC increased its holdings in Agios Pharmaceuticals by 554.7% in the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 1,836 shares during the period. Finally, Quantbot Technologies LP acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at approximately $146,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.